Trump's Tariff Warning Sparks Fresh Selloff in Pharma Stocks

A fresh Trump tariff warning dragged pharma stocks lower on Tuesday. Investors turned cautious after Donald Trump proposed steep duties on imported generic drugs.

The announcement raised concerns about export earnings for Indian pharma companies. Stocks of Glenmark, Biocon, and Aurobindo Pharma were among the biggest losers. The latest Trump tariff proposal has again shifted market focus to the sector's dependence on the US market.

Pharma Stocks Slide After Trump's Tariff Proposal

Selling pressure hit several drug makers after Trump announced plans to impose tariffs on imported generic medicines. He said companies would get up to two years to shift manufacturing to the US. After that, imported medicines could face tariffs of up to 200%.

The announcement hurt investor sentiment across the sector.

Some of the major declines included:

• Glenmark Pharmaceuticals fell around 3%.
• Biocon dropped nearly 3%.
• Aurobindo Pharma also lost close to 3%.
• Other pharmaceutical companies also traded lower during the session.

The Nifty Pharma index remained under pressure as investors assessed the possible impact of the proposal.

Why Indian Pharma Companies Are Worried

The United States remains the biggest export market for many Indian drug manufacturers. Generic medicines contribute a large share of their revenue.

A sharp increase in US import duties could:

• Raise the cost of selling medicines in America.
• Reduce the price advantage of Indian manufacturers.
• Increase pressure on company margins.
• Force firms to expand manufacturing inside the US.

Companies with greater exposure to the US market may face more pressure if the proposal becomes law. However, the plan is still a proposal. The final policy, implementation timeline, and exemptions remain unclear.

Also Read: The Hidden Health Risks of Sitting All Day

Analysts Say Long-Term Impact Depends on Final Policy

Market experts believe investors reacted quickly because of uncertainty. They noted that Trump's comments do not immediately change existing trade rules. Many analysts expect companies to wait for official policy details before making major investment decisions.

Several Indian pharmaceutical companies already operate manufacturing facilities in the US. Others may consider expanding their presence if higher tariffs become a reality.

Despite the market reaction, experts say the sector's long-term outlook will depend on:

• The final tariff structure.
• Implementation timelines.
• Product-specific exemptions.
• Future US trade policy after the proposal.

For now, investors are likely to keep a close watch on further announcements from the US. Any clarity could decide the next move in pharmaceutical stocks.